Alnylam Pharmaceuticals, Inc. (ALNY)
267.29
+21.18
(+8.61%)
USD |
NASDAQ |
Sep 02, 16:00
266.00
-1.29
(-0.48%)
After-Hours: 18:50
Alnylam Pharmaceuticals Research and Development Expense (TTM) : 1.509B for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 1.509B |
| March 31, 2026 | 1.420B |
| December 31, 2025 | 1.320B |
| September 30, 2025 | 1.248B |
| June 30, 2025 | 1.160B |
| March 31, 2025 | 1.130B |
| December 31, 2024 | 1.126B |
| September 30, 2024 | 1.098B |
| June 30, 2024 | 1.080B |
| March 31, 2024 | 1.035B |
| December 31, 2023 | 1.004B |
| September 30, 2023 | 994.31M |
| June 30, 2023 | 986.50M |
| March 31, 2023 | 943.69M |
| December 31, 2022 | 883.02M |
| September 30, 2022 | 850.03M |
| June 30, 2022 | 799.23M |
| March 31, 2022 | 776.15M |
| December 31, 2021 | 792.16M |
| September 30, 2021 | 731.58M |
| June 30, 2021 | 698.79M |
| March 31, 2021 | 671.15M |
| December 31, 2020 | 654.82M |
| September 30, 2020 | 687.65M |
| June 30, 2020 | 686.66M |
| Date | Value |
|---|---|
| March 31, 2020 | 695.56M |
| December 31, 2019 | 655.11M |
| September 30, 2019 | 584.85M |
| June 30, 2019 | 564.00M |
| March 31, 2019 | 537.69M |
| December 31, 2018 | 505.42M |
| September 30, 2018 | 492.16M |
| June 30, 2018 | 447.46M |
| March 31, 2018 | 400.51M |
| December 31, 2017 | 390.64M |
| September 30, 2017 | 377.87M |
| June 30, 2017 | 380.56M |
| March 31, 2017 | 373.10M |
| December 31, 2016 | 382.39M |
| September 30, 2016 | 360.22M |
| June 30, 2016 | 330.90M |
| March 31, 2016 | 314.73M |
| December 31, 2015 | 276.50M |
| September 30, 2015 | 249.21M |
| June 30, 2015 | 226.86M |
| March 31, 2015 | 204.53M |
| December 31, 2014 | 190.25M |
| September 30, 2014 | 166.81M |
| June 30, 2014 | 154.99M |
| March 31, 2014 | 134.54M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Ionis Pharmaceuticals, Inc. | 923.08M |
| BridgeBio Pharma, Inc. | 505.38M |
| Regeneron Pharmaceuticals, Inc. | 5.748B |
| Vertex Pharmaceuticals, Inc. | 3.907B |
| Pfizer Inc. | 10.82B |